NCT00687765View on ClinicalTrials.gov

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Glioblastoma
Interventions
DRUG

bsi-201 plus temozolomide

BSI-201 given iv. 2x weekly, temozolomide given orally

Trial Locations (8)

19104

Research Site, Philadelphia

27157

Research Site, Winston-Salem

30322

Research Site, Atlanta

33612

Research Site, Tampa

35294

Research Site, Birmingham

48202

Research Site, Detroit

92114

Research Site, Boston

Unknown

Research Site, Baltimore

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00687765 - Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma | Biotech Hunter | Biotech Hunter